KLP Kapitalforvaltning AS Invests $536,000 in Scholar Rock Holding Co. (NASDAQ:SRRK)

KLP Kapitalforvaltning AS acquired a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,400 shares of the company’s stock, valued at approximately $536,000.

Several other institutional investors and hedge funds have also bought and sold shares of SRRK. Sei Investments Co. lifted its holdings in Scholar Rock by 4.



7% during the fourth quarter. Sei Investments Co. now owns 87,314 shares of the company’s stock valued at $3,774,000 after purchasing an additional 3,940 shares during the last quarter.

American Century Companies Inc. bought a new stake in shares of Scholar Rock in the fourth quarter valued at approximately $28,394,000. Teacher Retirement System of Texas lifted its stake in shares of Scholar Rock by 58.

1% during the 4th quarter. Teacher Retirement System of Texas now owns 17,390 shares of the company’s stock valued at $752,000 after buying an additional 6,388 shares in the last quarter. Xponance Inc.

bought a new position in Scholar Rock in the 4th quarter worth approximately $241,000. Finally, Cibc World Markets Corp purchased a new position in Scholar Rock in the 4th quarter valued at approximately $314,000. 91.

08% of the stock is owned by institutional investors. Insider Transactions at Scholar RockIn other news, insider Tracey Sacco sold 6,500 shares of the business’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $33.

08, for a total transaction of $215,020.00. Following the completion of the transaction, the insider now owns 71,750 shares of the company’s stock, valued at approximately $2,373,490.

The trade was a 8.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Also, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.

52. Following the completion of the sale, the director now directly owns 30,319 shares in the company, valued at $1,043,579.98.

This represents a 3.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Over the last quarter, insiders have sold 299,772 shares of company stock valued at $11,245,798. 19.20% of the stock is currently owned by company insiders.

Analyst Upgrades and DowngradesSeparately, Wedbush restated an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.

com, the stock has an average rating of “Buy” and an average target price of $42.67.Read Our Latest Research Report on Scholar RockScholar Rock Stock PerformanceScholar Rock stock opened at $30.

70 on Friday. The firm’s 50 day simple moving average is $36.64 and its 200 day simple moving average is $33.

52. The company has a current ratio of 3.88, a quick ratio of 3.

88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co.

has a 1-year low of $6.76 and a 1-year high of $46.98.

The firm has a market capitalization of $2.91 billion, a PE ratio of -13.06 and a beta of 0.

56. Scholar Rock Company Profile (Free Report)Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Featured StoriesFive stocks we like better than Scholar RockWhat is a Secondary Public Offering? What Investors Need to KnowShares of RH Down Nearly 40%: Where Investors Can Turn To NowHow to Invest in the Best Canadian Stocks Tariffs, Spin-Out, and R2 Updates Are Positive Signs for RivianHow to trade using analyst ratingsCathie Wood Loads Up on Baidu—Is It the Right Time to Buy?Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report).

.